ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?

Intuitive Surgical (ISRG) shares have declined 13.4% in the last three months, underperforming peers, primarily due to concerns over a projected 200-300 basis point gross margin contraction in 2025 driven by tariffs and product mix shifts, which is expected to pressure Q4 earnings. Despite strong da Vinci procedure growth (guidance raised to 15.5-17%) and high recurring revenue (85%), headwinds include rising competition, international budget constraints, and moderating bariatric procedure demand from GLP-1 drugs. The stock is also considered overvalued at 50.56x forward P/E, suggesting near-term volatility despite its market leadership.

Analysis

Intuitive Surgical (ISRG) presents a mixed outlook where strong top-line momentum is being challenged by significant margin pressures and external headwinds. Despite a 13.4% share price decline over three months, underperforming peers Johnson & Johnson and Medtronic, the company demonstrates robust fundamentals through a solid recurring revenue model, which constitutes 85% of H1 2025 sales, and an upgraded full-year procedure growth forecast of 15.5-17%. However, these strengths are overshadowed by a projected 200-300 basis point contraction in adjusted gross margin for 2025, attributed to product mix, tariffs, and costs associated with the new da Vinci 5 system. This margin erosion is expected to cause a divergence between revenue and profit growth, with Q4 earnings projected to decline 1.8% year-over-year. Additional risks include moderating bariatric procedure growth due to GLP-1 drugs, intensifying competition from lower-cost systems by Medtronic and Johnson & Johnson, and international budget constraints limiting new system adoption. The stock's premium valuation, trading at a 50.56x forward P/E multiple compared to the sector's 27.51x, and its position below key moving averages, suggest further near-term price volatility.

Key Decisions for Investors

• Investors should weigh ISRG's strong procedure growth and market leadership against the significant near-term headwinds of gross margin contraction and a premium valuation.
• Monitor the company's quarterly earnings closely for any stabilization or further deterioration in gross margins, as the projected 200-300 bps decline in 2025 is the primary driver of negative sentiment.
• Assess the competitive threat from Medtronic's Hugo and Johnson & Johnson's Ottava systems, as their market penetration, particularly in cost-sensitive international regions, could impact ISRG's long-term pricing power and growth.
• Given the stock's technical weakness and the uncertainty surrounding the impact of GLP-1 drugs and tariffs, it may be prudent for new investors to await a more favorable entry point or for existing shareholders to consider hedging against near-term downside risk.